Poster Presentation Award #2 – 2025 of Targeting Phage Therapy 2025

 

Congratulations to Dr. Viviane de Cássia Oliveira for winning Poster Presentation Award 2025 !

Her poster, “Evolution of Ceftolozane/Tazobactam Resistance in Carbapenem-Resistant Pseudomonas aeruginosa Under Phage-Antibiotic” earned recognition by the scientific committee for its depth of analysis and relevance to one of today’s most critical challenges in antimicrobial resistance. Her research offers new insights into the complex interactions between phages and antibiotics, paving the way for more effective combination therapies in the fight against multidrug-resistant infections.

Summary and Future Steps of her Research

Approximately 20–36% of ventilated patients develop ventilator-associated pneumonia (VAP), frequently caused by Pseudomonas aeruginosa. VAP has a high mortality rate, ranging from 24% to 76%, and imposes a significant burden on healthcare resources. My research, developed under ARISTOS program (European Union’s Horizon Europe research – Marie Sklodowska-Curie actions), focuses on identifying novel therapeutic approaches for treating VAP caused by carbapenem-resistant P. aeruginosa, a high-priority pathogen according to the WHO. The next phase of my study involves the in vivo administration of phage cocktails, evaluating their effect on progression and severity of VAP, alongside investigating how different lung cells respond to phage therapy. In parallel, the inhibition of biofilm formation on endotracheal tubes will be also investigated. I am committed to exploring the effect of phage-therapy against acute multidrug-resistant infections, which are widely regarded as one of the most critical global health challenges.

Bravo to Dr. Oliveira for this remarkable contribution and well-deserved recognition!

 

        

Share with: